SEC Form 4 · accession 0000899243-17-024252

SCICLONE PHARMACEUTICALS INC · SCLN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — General Counsel

Period of report

Oct 13, 2017

Accepted (ET)

Oct 16, 2017 · 5:07 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000880771

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2	Oct 13, 2017	M	30,000	—	A	31,982	D
Common Stock	Oct 13, 2017	F	11,274	$11.18	D	20,708	D
Common Stock	Oct 13, 2017	D	20,708	$11.18	A	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Incentive Stock Option (right to buy)^F3,F5,F4	$10.35	Oct 13, 2017	D	38,644	D	—	Nov 14, 2026	Common Stock	38,644	D
Non-Qualified Stock Option (right to buy)^F3,F5,F4	$10.35	Oct 13, 2017	D	41,356	D	—	Nov 14, 2026	Common Stock	41,356	D
Restricted Stock Unit^F3,F1,F6	—	Oct 13, 2017	M	30,000	D	—	—	Common Stock	30,000	D

F1Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
F2Includes 773 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on May 31, 2017; 746 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on August 31, 2017; and 463 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on October 6, 2017.
F3Granted under Issuer's 2015 Equity Incentive Plan.
F4Under its terms the option became exercisable in installments with 25% vesting on October 24, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger").
F5The option was canceled immediately prior to the Merger in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
F6Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.